Negotiamini Media
Truth is Powerful

Healthcare & Life Science M&A Activity Plummets 1H’22


What You Should Know:

– The index of Healthcare & Life Science equities tracked by Stout was down 16.8% in Q2 2022, which was in line with the S&P 500 decline of 16.4%.

– Healthcare & Life Science M&A activity plummeted to 338 deals in Q2 2022 versus 535 in Q2 2021 and a record 565 deals in Q4 2021. The report reveals credit markets likely to tighten, but a healthy level of M&A is expected to continue in the growing and defensive healthcare sector. Key Trends and Market Summary

For more than 30 years, Stout has exclusively focused on serving the unique M&A transaction advisory needs of middle-market clients. It is a trusted advisor to leading organizations due to its deep industry knowledge, senior-level attention, process expertise, and relentless focus on delivering unparalleled results.

The key trends highlighted in the Quarterly Update Q2 2022 report from Stout are as follows:

1. Health Service Equities and Big Pharma: Healthcare Service equities underperformed the S&P 500, but the outperformance of the Big Pharma and Biotech sub-sectors allowed healthcare overall to keep pace with the market. Hospital stocks dropped 32.6% in the second quarter and were the worst performing sub-sector tracked by Stout […]

Click here to view original web page at


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More